Classifications: vasodilator; phosphodiesterase inhibitor; antiplatelet agent; Therapeutic: peripheral vasodilator
Pregnancy Category: C
50 mg, 100 mg tablets
Inhibition of an isoenzyme which results in vasodilatation and inhibition of platelet aggregation induced by collagen or
Increases the skin temperature of the extremities and improves claudication. Effectiveness is indicated by increased ability
to walk further without claudication.
Congestive heart failure of any severity; hypersensitivity to cilostazol; acute MI; hemostatic disorders or pathologic bleeding;
pregnancy (category C), lactation.
Cardiac arrhythmias, MI within 6 mo; valvular heart disease; peptic ulcer disease; renal failure. Safety and efficacy in
children <18 y are not established.
Route & Dosage
- Give at least ? h before or 2 h after a meal. Do not give with grapefruit juice.
- Store at 20°25° C (68°77° F).
Adverse Effects (≥1%) Body as a Whole:
Back pain, headache,
infection, myalgia. CNS:
Dizziness, vertigo. CV:
Palpitations, tachycardia. GI:
Abdominal pain, abnormal stools, diarrhea,
dyspepsia, flatulence, nausea. Respiratory:
Cough, pharyngitis, rhinitis.
InteractionsDrug: Aspirin, clopidogrel, diltiazem, erythromycin, fluconazole, fluvoxamine, fluoxetine, ketoconazole, itraconazole, macrolide antibiotics
, miconazole, nefazodone, omeprazole, sertraline
may increase cilostazol
High fat meals may increase peak concentrations. Grapefruit juice
may increase concentration.
Well absorbed from GI tract. Onset:
24 wk. Distribution:
9598% protein bound. Smoking may decrease serum levels. May be excreted in breast milk. Metabolism:
Metabolized by CYP3A4 to active metabolites. Elimination:
Metabolites primarily excreted in urine. Half-Life:
Assessment & Drug Effects
- Monitor therapeutic effectiveness indicated by ability to walk farther without leg pain.
- Monitor for S&S of CHF. Do not give cilostazol to patients with preexisting CHF.
Patient & Family Education
- Avoid grapefruit or grapefruit juice while taking cilostazol.
- Allow 212 wk for therapeutic response.